Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment
AJ Matar, V Pathiraja, Z Wang, R Duran-Struuck… - Transplant …, 2012 - Elsevier
Diphtheria toxin (DT)-based anti-CD3 immunotoxins have clinical relevance in numerous
applications including autoimmune disease therapies and organ transplantation tolerance
protocols. Pre-existing anti-DT antibodies acquired either by vaccination against diphtheria
toxin or infections with C. diphtheriae may interfere or inhibit the function of these anti-CD3
immunotoxins. Previously, a full-length anti-rhesus monkey CD3 immunotoxin, FN18-CRM9,
was shown to be less effective at depleting circulating T cells in animals with pre-existing …
applications including autoimmune disease therapies and organ transplantation tolerance
protocols. Pre-existing anti-DT antibodies acquired either by vaccination against diphtheria
toxin or infections with C. diphtheriae may interfere or inhibit the function of these anti-CD3
immunotoxins. Previously, a full-length anti-rhesus monkey CD3 immunotoxin, FN18-CRM9,
was shown to be less effective at depleting circulating T cells in animals with pre-existing …